Liquid biopsy has reshaped how researchers and clinicians think about tumor biology, treatment monitoring, and early cancer detection. As programs advance from discovery to clinical validation, the biospecimen sourcing decisions made early in a study have an outsized impact on data quality and regulatory readiness. Understanding what your analyte actually is, and what that requires at the collection and procurement level, is where that planning has to start.
The Liquid Biopsy Analyte Landscape
The liquid biopsy field encompasses several distinct analyte classes, each with its own biology and sourcing requirements. The three most clinically mature are cfDNA, ctDNA, and circulating tumor cells (CTCs). Emerging analytes — including circulating tumor RNA (ctRNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) — are generating real scientific interest but remain earlier in clinical development. This post focuses on the three analytes most commonly encountered in translational research and assay validation programs today.
Cell-free DNA (cfDNA) refers to all DNA fragments circulating in plasma, shed through normal cell turnover, apoptosis, and necrosis across a wide variety of cell types. In any individual, most cfDNA originates from non-tumor sources.
Circulating tumor DNA (ctDNA) is the tumor-derived subset of cfDNA. It carries the somatic mutations, copy number alterations, and epigenetic signatures of the underlying malignancy. In early-stage cancers, ctDNA may represent less than 0.1% of total cfDNA. In advanced disease that fraction rises, but the tumor signal is always embedded within a much larger background of normal cell-free fragments.
Many modern assays blur the line between the two. Grail’s Galleri test, for example, analyzes cfDNA broadly through methylation profiling but is specifically hunting for tumor-derived signal — making its procurement requirements closer to ctDNA than the cfDNA label might suggest. Understanding where your assay falls on this spectrum matters for how you source.
Circulating tumor cells (CTCs) are intact cells shed directly from the tumor into the bloodstream. Unlike cfDNA and ctDNA, which are analyzed from plasma, CTCs are captured from whole blood using filtration or immunomagnetic selection — CellSearch remains the only FDA-cleared CTC platform, though newer approaches are in active development. Because CTCs are intact cells, they enable analyses that cell-free approaches cannot: direct morphological assessment, single-cell sequencing, and ex vivo culture. The tradeoff is a collection workflow that is significantly more logistically constrained.
What Each Analyte Requires at the Collection Level
Collection Tube Selection: Where cfDNA and ctDNA Diverge Most
This is the single most consequential pre-analytical decision, and it affects cfDNA and ctDNA programs differently.
Standard EDTA tubes do not inhibit white blood cell (WBC) lysis after collection. As WBCs lyse ex vivo, they release genomic DNA into the plasma — DNA that is indistinguishable from legitimate cfDNA by most downstream assays. For cfDNA applications, this inflates total yield with artifactual signal and distorts fragment size distributions. For ctDNA specifically, the effect is more damaging: the flood of normal genomic DNA from lysing WBCs dilutes the tumor-derived fraction, collapsing the variant allele frequency (VAF) and potentially pushing ctDNA signal below the limit of detection of even sensitive assays.
Cell-stabilizing collection tubes — Streck BCT tubes and Qiagen’s PAXgene Blood ccfDNA tubes being the most widely used — prevent WBC lysis through a fixative chemistry that maintains cell membrane integrity for up to 14 days at ambient temperature. This preserves the cfDNA pool as it existed at the moment of collection, without contamination from genomic DNA. For ctDNA programs where VAF is a primary outcome and low-abundance variants must be reliably detected, Streck or equivalent stabilization tubes are effectively required. For cfDNA programs where fragment integrity and size distribution matter, they are strongly preferred.
Methylation-based cfDNA assays face an additional and separate challenge. Bisulfite conversion — the chemical treatment required to read methylation marks — is inherently degradative; it chemically modifies and fragments DNA as part of the process. Stabilization tubes help by delivering the most intact possible starting material, which reduces one source of pre-analytical degradation, but they do not eliminate the bisulfite-induced degradation that occurs during the assay itself. The practical implication is that for methylation-based programs, pre-analytical discipline matters even more than for mutation-detection approaches — because the assay chemistry is already working against fragment integrity, any additional degradation upstream compounds the problem.
The practical implication: tube type should be specified in the collection protocol, not left to site default practice. Mixing tube types across sites or timepoints introduces a source of variability that is difficult to correct analytically.
Donor Eligibility and Clinical Annotation
The difference in annotation requirements between ctDNA and cfDNA programs comes down to what each assay is actually measuring.
ctDNA mutation-detection assays are chasing a specific somatic variant at very low allele frequency — sometimes below 0.5% of total cfDNA. That signal is acutely sensitive to the donor’s clinical state. Tumor burden drives how much ctDNA is present; treatment can suppress it dramatically, sometimes to undetectable levels within days of the first cycle; and the timing of the draw relative to therapy can shift VAF enough to render a sample uninterpretable for validation purposes. A pre-treatment sample and a mid-chemotherapy sample from the same patient can look entirely different. Without tight clinical annotation, you cannot stratify samples appropriately and the data loses its meaning. For ctDNA programs, the following fields are not optional:
- Confirmed pathologic diagnosis, histological subtype, and TNM staging
- Treatment-naive status or full treatment history at time of collection
- Collection timing relative to therapy (pre-treatment, on-treatment cycle, post-treatment, surveillance)
- Comorbidities and concurrent medications that may affect cfDNA levels
cfDNA pattern-based assays — fragmentomics, methylation profiling — measure a broad molecular landscape across millions of fragments rather than hunting for a specific variant. That signal is more resilient to clinical fluctuation, not because treatment doesn’t affect cfDNA (it does — widespread cell death from chemotherapy alters the cfDNA pool), but because you are classifying a diffuse population-level signature rather than detecting a precise low-abundance target. Annotation is still meaningful, but the dependency on exactly where in the treatment course a sample was drawn is less acute. Good annotation remains best practice; it is simply less likely to make or break the scientific validity of an individual sample.
Matched Tissue: Required for ctDNA, Context-Dependent for cfDNA
For ctDNA assay validation — including regulatory submissions for tests like Guardant360 or Foundation Medicine’s FoundationOne Liquid CDx — matched FFPE tumor tissue from the same patient is frequently required. The reason is concordance: regulators and study designers need to confirm that variants detected in plasma are present in the primary tumor, establishing that the liquid biopsy signal is genuinely tumor-derived. Without matched tissue, that confirmation is not possible.
For cfDNA applications that rely on methylation classifiers or fragmentomics rather than somatic variant detection, matched tissue requirements are less universal. However, programs training machine learning models on cfDNA signal may still want matched tissue to build ground truth labels for tumor vs. normal classification — so the need depends on the specific application and study design.
CTCs: A Fundamentally Different Collection Workflow
CTC collection shares the blood draw starting point with cfDNA and ctDNA but diverges sharply from there. The key constraints:
- Specialized collection tubes are required. CellSave Preservative Tubes (Menarini Silicon Biosystems) are designed to stabilize intact CTCs in whole blood for up to 96 hours at ambient temperature. Standard EDTA or Streck tubes are not appropriate for CTC capture workflows.
- Fresh processing is the norm. Many CTC isolation platforms — particularly those designed for downstream culture or single-cell analysis — require same-day or next-day processing. Unlike plasma for cfDNA, CTC specimens generally cannot be banked and thawed.
- CTC yield is highly variable and often low. Even in metastatic disease, CTC counts can be in the single digits per 7.5 mL of blood. This has implications for study powering, donor eligibility criteria, and the volume of blood required per draw.
- Shipping logistics require careful planning. Because fresh whole blood must reach the processing lab within a defined window, site geography and courier logistics are part of the collection design in a way that plasma-based studies can partially avoid through stabilization tubes.
For CTC programs, the conversation with a biospecimen partner needs to cover processing location, courier SOP, and acceptable transit times before any other design decisions are made. MT Group’s founders served as consultants during the launch of the CellSearch platform, giving our team firsthand familiarity with the operational and pre-analytical requirements that CTC programs demand.
Specifying the Right Specimens
When scoping a cfDNA, ctDNA, or CTC procurement with a biospecimen partner, the conversation should address:
- Analyte and tube type — Specify collection tube upfront for each analyte; cfDNA/ctDNA programs should specify Streck or PAXgene; CTC programs require CellSave or platform-specific tubes
- Diagnosis and annotation depth — Confirmed pathology, staging, treatment status, and collection timing relative to therapy
- Matched tissue requirement — Whether FFPE from the same patient is needed, and whether molecular profiling of the primary tumor is required before specimen release
- Volume per draw — ctDNA assays may require 4–10 mL of plasma per subject; CTC platforms typically require 7.5 mL whole blood per subject; confirm requirements before activating sites
- Processing SOP and logistics — For plasma: double-spin centrifugation protocol, time-to-processing limits, and freeze-thaw tracking. For CTCs: transit time windows and processing location must be locked before collection begins
The Bottom Line
cfDNA, ctDNA, and CTCs are related but distinct analytes, and the sourcing requirements that follow from each are meaningfully different. Tube selection, donor eligibility criteria, matched tissue requirements, and processing logistics all depend on what your assay is actually measuring and what clinical or regulatory standard it needs to meet.
Getting these decisions right at study design — before a protocol is locked and sites are activated — is where a knowledgeable biospecimen partner adds the most value. If you are scoping a liquid biopsy collection and want to think through the design, we’d like to hear from you.
MT Group is a biospecimen contract research organization with over 22 years of experience in prospective collection, longitudinal study design, and clinically annotated biospecimen supply. When you need something specific, we’re the group to talk to.
